Learning Objectives:
  1. Identify novel inflammatory pathways being studied for upcoming therapeutic interventions.
  2. Identify the patient safety risk factors associated with novel therapeutics in IBD.
  3. Identify the potential roles for combination of novel therapies for the treatment of IBD.
Session date: 
06/04/2024 - 4:30pm to 5:30pm CDT
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Russell D. Cohen, MD, FACG, AGAF